FindTrial
Sign In

Dose-ranging trial of OPC-249 powder inhalation in patients with pain due to osteoporosis

Dose-ranging trial of OPC-249 powder inhalation in patients with pain due to osteoporosis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220414
Enrollment
Unknown
Registered
2007-07-13
Start date
2007-07-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain due to osteoporosis

Interventions

investigational material(s) Generic name etc : OPC-249 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients who fulfill all of the following items -Patients with primary osteoporosis -Patients who have existing 1-4 vertebral fractures -Patients with back pain persisting for one week or more -Postmenopausal women between 46 and less than 80 years of age

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026